Patient demographics
| Patient characteristics . | N = 20 . |
|---|---|
| Median age, y (range) | 61 (30-74) |
| Male sex | 12 (60) |
| Race | |
| Black or African American | 1 (5) |
| Asian | 4 (20) |
| White | 15 (75) |
| Ethnicity | |
| Non-Hispanic or non-Latino | 17 (85) |
| Hispanic or Latino | 3 (15) |
| ECOG PS score | |
| 0 | 3 (15) |
| 1 | 16 (80) |
| 2 | 1 (5) |
| Diagnosis | |
| AML | 19 (95) |
| MDS/AML with mutated TP53 | 1 (5) |
| Disease status at enrollment | |
| ND | 6 (30) |
| Relapsed | 14 (70) |
| Median prior lines of treatment for relapsed patients (range) | 1 (1-3) |
| No. of patients relapsed after HCT | 4 (29) |
| Secondary AML | 6 (30) |
| Treatment-related AML | 3 (15) |
| ELN 2017 risk category | |
| Favorable | 4 (20) |
| Intermediate | 4 (20) |
| Adverse | 12 (60) |
| Patient characteristics . | N = 20 . |
|---|---|
| Median age, y (range) | 61 (30-74) |
| Male sex | 12 (60) |
| Race | |
| Black or African American | 1 (5) |
| Asian | 4 (20) |
| White | 15 (75) |
| Ethnicity | |
| Non-Hispanic or non-Latino | 17 (85) |
| Hispanic or Latino | 3 (15) |
| ECOG PS score | |
| 0 | 3 (15) |
| 1 | 16 (80) |
| 2 | 1 (5) |
| Diagnosis | |
| AML | 19 (95) |
| MDS/AML with mutated TP53 | 1 (5) |
| Disease status at enrollment | |
| ND | 6 (30) |
| Relapsed | 14 (70) |
| Median prior lines of treatment for relapsed patients (range) | 1 (1-3) |
| No. of patients relapsed after HCT | 4 (29) |
| Secondary AML | 6 (30) |
| Treatment-related AML | 3 (15) |
| ELN 2017 risk category | |
| Favorable | 4 (20) |
| Intermediate | 4 (20) |
| Adverse | 12 (60) |
Data are presented as number (%), unless otherwise stated.
ECOG PS, Eastern Cooperative Oncology Group performance status; MDS, myelodysplastic syndrome.